For millions of women, the annual pelvic exam begins with a moment of cold metal. The speculum, a tool whose basic design has remained largely unchanged for over a century, is a source of documented anxiety, discomfort, and for some, a barrier to routine cervical cancer screening. SakuraMed, a startup born in a University of Illinois bioengineering lab, is betting that a piece of familiar, patient-controlled hardware can change that clinical moment. Its proposed replacement is a self-insertable, tampon-shaped imaging device designed to capture cervical visuals without the duckbill. It is a hardware bet on patient dignity, aiming to thread the needle between clinical necessity and humane care.
The company, founded in 2022 by then-student Priya Kumar, is now navigating the long road of medical device validation. It has secured modest non-dilutive funding through university competitions and is actively seeking its first institutional round to fund the regulatory pathway. For a device that must meet the FDA's Class II standards for diagnostic imaging, the journey from a functional prototype to a cleared product is measured in years and millions. SakuraMed’s early traction is measured not in revenue, but in letters of intent from major academic medical centers willing to test its latest prototypes.
The clinical wedge: comfort as a catalyst
SakuraMed’s fundamental premise is that improving the patient experience is not merely a nicety, but a clinical and commercial lever. Discomfort with the speculum is a well-documented factor in delayed screenings. The company’s device, which features a disposable casing and a reusable imaging core, is designed to be patient-inserted, shifting control and potentially reducing the anxiety tied to the clinician-controlled speculum [PERPLEXITY SONAR PRO BRIEF]. The goal is to offer a workflow that clinicians accept and patients prefer, creating a pull-through demand from both sides of the exam table.
Internally, the company cites a 2025 U.S. study where over 75% of patients preferred its prototype to a standard speculum [PERPLEXITY SONAR PRO BRIEF]. That data point, while compelling, lacks the published protocol and peer review that would give it weight with regulators and institutional buyers. It underscores the company’s mission-driven focus, but also highlights the evidence gap that must be closed through formal clinical trials. The real validation will come from the studies it is now pursuing with partner hospitals.
The validation pathway
For a pre-revenue medical device startup, traction is defined by clinical partnerships. SakuraMed is not yet selling; it is testing. The company reports it is pursuing validation work with clinicians at the University of Chicago, Cleveland Clinic, and Cook County Hospital [PERPLEXITY SONAR PRO BRIEF]. These are not commercial contracts, but crucial collaborative relationships where clinicians provide feedback on prototype iterations and study protocols. Landing these names speaks to the clinical interest in the problem space, even at this early stage.
A key figure on this path is Dr. Samantha Yee, listed as the company’s Chief Science Officer [PERPLEXITY SONAR PRO BRIEF]. Her role, alongside advisor Craig Scherer, a medtech investor, suggests an effort to build the scientific and regulatory scaffolding required to navigate the FDA [Craig Scherer, November 2025]. The team’s composition reflects the dual challenge: bioengineering innovation paired with med-device development rigor.
| Role | Name | Background / Note |
|---|---|---|
| Founder & CEO | Priya Kumar | UIUC bioengineering student; founded company after personal screening discomfort [PERPLEXITY SONAR PRO BRIEF]. |
| Chief Science Officer | Dr. Samantha Yee | Leads scientific and clinical validation strategy [PERPLEXITY SONAR PRO BRIEF]. |
| Hardware Lead | Karan Jain | Associated with hardware product development [SignalHire, 2026]. |
| Advisor | Craig Scherer | Medtech investor and device development advisor [gritt.io, 2026]. |
Funding the long regulatory haul
To date, SakuraMed’s financial runway has been built from non-dilutive sources. Reports indicate it has raised approximately $65,000 in grant and competition funding, including support from the university’s iVenture Accelerator and New Venture Challenge [Craig Scherer, November 2025] [Oncode Institute, June 2026]. This is a common starting point for academic spin-outs, but it is capital designed for prototyping, not for funding pivotal trials.
The company’s public target is a $1.2 million raise to achieve its first FDA approvals [PERPLEXITY SONAR PRO BRIEF]. That figure aligns with the early costs of a 510(k) submission for a novel imaging device, covering final design iterations, biocompatibility testing, and a limited clinical study for submission. It is a pre-seed round in name, but its purpose is squarely in the realm of regulatory de-risking.
The risks on the shelf
The ambition is clear, but the path is lined with hurdles specific to regulated hardware. SakuraMed’s success hinges on clearing obstacles that have ended many medtech ventures.
- Clinical evidence. The cited patient preference data is an encouraging signal, but the FDA will require rigorous, controlled studies proving the device is as safe and effective as the predicate,the speculum,for visualizing the cervix. Designing and executing that trial is a multi-year, multi-million dollar endeavor.
- Manufacturing and cost. The business model relies on a disposable casing and reusable core. Scaling reliable, sterile manufacturing for a single-use medical device while maintaining a cost profile acceptable to hospitals is a classic medtech challenge that cannot be solved in a lab.
- Market adoption. Even with FDA clearance, convincing hospital procurement to switch from a cheap, ubiquitous tool like the speculum (a market valued at nearly $9 billion) requires demonstrating undeniable workflow improvement or cost savings [The Business Research Company]. Clinician training and patient education become part of the sales cycle.
The company’s most plausible answer to these risks is its staged approach: focusing first on validation partnerships, then a targeted fundraise for the submission, avoiding the trap of over-promising before the clinical data is in.
The next twelve months
The coming year is a critical proof-of-concept window for SakuraMed. The key milestones are less about revenue and more about generating the data that makes the larger fundraise possible. Success looks like completing a structured feasibility study with one of its hospital partners, locking in the final device design based on that feedback, and securing the targeted $1.2 million to officially begin the FDA submission process. A misstep would be expanding too quickly before the clinical feedback is fully integrated, risking a design that doesn’t meet real-world clinician needs.
For patients requiring routine cervical cancer screening or diagnostic pelvic exams, the standard of care today is defined by a legacy of discomfort. The speculum, for all its clinical utility, remains a symbol of a passive and often distressing experience. SakuraMed is attempting to rewrite that experience by putting the form factor of patient comfort at the center of the diagnostic process. Its bet is that better design can lead to better health outcomes, not by replacing the clinician’s eye, but by changing what the patient feels in the moments before the exam begins. The road from Champaign to the clinic is long, but it starts with a simple, humane premise: the tool itself shouldn't be the hardest part of getting care.
Sources
- [PERPLEXITY SONAR PRO BRIEF] SakuraMed company and product overview | https://www.sakuramedtech.com/
- [Craig Scherer, November 2025] The next Medtech company that I am profiling is SakuraMed | https://www.linkedin.com/posts/craig-scherer-2654254_the-next-medtech-company-that-i-am-profiling-activity-7391531426254475265-nRGi
- [Oncode Institute, June 2026] Oncode Institute annual report 2025,recap | https://www.linkedin.com/posts/oncode-institute_oncode-institute-annual-report-2025-recap-activity-7477654407443116034-snFb
- [SignalHire, 2026] Karan Jain profile | https://www.signalhire.com
- [gritt.io, 2026] Craig Scherer advisor profile | https://www.gritt.io
- [The Business Research Company] Vaginal Speculum market size report | https://www.thebusinessresearchcompany.com
- [Samantha Yee, X, 2026] Seeking clinician feedback for SakuraMed prototype | https://x.com
- [UniStart, February 2025] Startups of the Week: examine, Ardent AI, SakuraMed, Parla, Traba | https://unistart.io/blog/startups-of-the-week-examine-ardent-ai-sakuramed-parla-traba